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Abstract
This is the fourth yearly article in the Tourette Syndrome Research Highlights
series, summarizing research from 2017 relevant to Tourette syndrome and
other tic disorders. The authors briefly summarize reports they consider most
important or interesting. The highlights from 2018 article is being drafted on the
Authorea online authoring platform, and readers are encouraged to add
references or give feedback on our selections using the comments feature on
that page. After the calendar year ends, the article is submitted as the annual
update for the Tics collection on F1000Research.
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Introduction
This article is meant to disseminate recent scientific progress
on Gilles de la Tourette Syndrome (TS).

Methods
We searched PubMed from time to time using the search strategy “(“Tic Disorders”[MeSH] OR Tourette NOT Tourette[AU])
AND 2017[PDAT] NOT 1950:2016[PDAT]”. On 06 July 2018
this search returned 212 citations. Colleagues also recommended articles, and we attended medical conferences. We
selected material to be discussed in this review subjectively,
guided by our judgment of possible future impact on the field.

Results
A number of tic experts contributed to a review article on TS
(Robertson et al., 2017).

Phenomenology and natural history
Schaefer et al. (2017) describe 16 people with TS who had
experienced a clinical remission or marked improvement of
more than 1 year’s duration, followed by symptomatic worsening as adults, leading them again to seek treatment. On average
the “latent period” (the absence or substantial reduction in tics)
had lasted 16 years. Seven of them had worse tics when returning for care than they recalled as children. New substance use
was reported as a trigger for exacerbation in 5 patients. This
report strengthens evidence that even long-lasting symptomatic
improvement in tic disorders (TDs) may not always be permanent,
and that in fact the typical course of TS “is one of occasional
recurrences of mild tics throughout adult life” (Black et al., 2016;
Bruun & Budman, 1997); see also (Shapiro et al., 1988, p. 188;
Stárková, 1990; Singer, 2006).
Regarding natural course and history, the fate of non-tic
symptoms in TS has remained less well explored. A large Danish study reported follow-up data 6 years after enrolling 314
children and teenagers with TS, assessing tics and comorbidities
(mainly obsessive–compulsive disorder (OCD) and AttentionDeficit/Hyperactivity Disorder (ADHD); N=226 at follow-up)
(Groth et al., 2017). Most patients’ tics improved over time, but
almost a quarter of those over age 16 still had severe tics, and
only a sixth had no tics. The severity of OCD and ADHD declined
significantly during adolescence, suggesting a shift towards
so-called “pure” TS with age. Furthermore, the authors expected
tic-related impairment to improve with an age-related decline
in tic frequency and severity, but surprisingly the impairment
score did not reflect the improvement in tics.
A report on 606 patients with a movement disorder starting
in childhood produced an estimate for tic onset of 7.4 ± 3.8
years with a mean delay to diagnosis of 9.9 ± 11 years
(Bäumer et al., 2016).
Epidemiology. New and important findings this year involve
the previously unappreciated risk of death in TDs. Meier
et al. (2017) demonstrated that mortality rates are elevated in
TS and other TDs, with or without comorbidities. In a very
large epidemiological study, TDs in adults were associated with
a four-fold higher risk of suicide, with the risk not explained by

other psychiatric illness such as major depression (Fernández
de la Cruz et al., 2017b). These researchers analyzed 7736
TS/chronic tic disorder (CTD) cases in the Swedish National
Patient Register over a 44-year period (1969–2013) and compared them with control subjects from the general population. An
increased risk of both suicide and attempted suicide was observed
in TS/CTD patients, which was not solely dependent on psychiatric comorbidities. Tics that persisted beyond young adulthood
significantly predicted completed suicide. Thus, TS/CTD is a
serious medical condition that requires careful monitoring of
suicidality. The same group also found a 7- to 10-fold higher
risk of completed suicide in people with OCD, even after
controlling for comorbid diagnoses (Fernández de la Cruz et al.,
2017a).
Martino et al. (2017c) review screening instruments and rating
scales for TDs; see also (Augustine et al., 2017; Martino &
Pringsheim, 2017).
Transient environmental effects on tic severity. A study of 45
children with TS supported the typical antecedent–behavior–
consequence behavioral psychology model (Eaton et al., 2017).
Specifically, consequences of tics, “such as receiving accommodations or attention from others,” explained significantly
more variance in tic severity than did the child’s level of separation anxiety, though the latter was also a significant factor. This
study provides supportive evidence for the approach taken by
“CBIT-Jr,” a behavior therapy designed for younger children
with TS (Piacentini et al., 2015).
Other. Non-tic symptoms in TS are reviewed by Martino
et al. (2017b). Lee et al. (2017) used Taiwan’s National Health
Insurance Research Database to compare 1124 newly diagnosed
TS patients to controls in a 1:3 match. Sleep disorders were
twice as common in TS, and remained significantly higher
in TS after accounting for anxiety disorders, which were the
comorbid conditions associated with the highest risk. In a
sample of 811 TS subjects recruited for a genetics study, hair
pulling (3.8%) and skin picking (13.0%) disorders by DSM-5
were surprisingly common (Greenberg et al., 2018).
Autism spectrum disorders (ASD) comprise an underexplored
comorbidity of TD. There are few epidemiological studies on
the subject but the prevalence of ASD in children with TDs is
estimated at 20% (Khalifa & von Knorring, 2006). In a large
study including patients with TD (n=535) and their family
members (n=234), Darrow et al. (2017a) used the Social Responsiveness Scale Second Edition (SRS) to characterize ASD
symptoms, and compared them to historical ASD samples. SRS
scores in participants with TD were similar to those observed
in other clinical samples but lower than in ASD samples. This
is mostly but not entirely explained by elevations in the RRB
(restricted interests and repetitive behaviors) subscale, which may
be indicating tics rather than other stereotypic movements. The
presence of OCD was associated with higher scores on the social
cognition and RRB subscales. Complex tics and OCD symptoms
(repetitive behaviors) can also be hard to discriminate from core
ASD symptoms, especially those related to social communication.
Page 2 of 13

F1000Research 2018, 7:1122 Last updated: 10 SEP 2018

Etiology
A national database study found that parents of children with
chronic tics had significantly higher rates of psychiatric illness:
more than twice as high in mothers and 39% higher in fathers
(Leivonen et al., 2017). The maternal risk, which included a
range of psychopathology, was significantly higher than the paternal risk, which comprised primarily OCD and anxiety disorders.
Further work will be needed to clarify whether results reflect
maternal-specific environmental risks, genetic risks, factors related
to parental care-seeking, or (to a modest extent, given the typical
ages of onset for various parental disorders identified) parental
stress.

A gene identified in human OCD, slc1a1, which codes an
excitatory amino acid transporter, was altered in mice to prevent
its expression and function (Zike et al., 2017). The loss of this
protein resulted in mice with reduced extracellular dopamine
concentrations and reduced movement and stereotypic behavior
after challenge with amphetamine or a dopamine D1 receptor
agonist. Restoring the gene’s expression in the midbrain, but
not in the striatum, partially rescued the exogenous dopamineinduced stereotypies. This research is important for its direct
links to human illness and its anatomical specificity, and lends
additional support to testing dopamine D1 antagonists in TS
(see Medication section, below).

Genetics. A large mixed genetic sample yielded two heritable
collections of symptoms that cross diagnostic boundaries, here
named symmetry (including some other obsessions and compulsions) and disinhibition (including complex verbal tics)
(Darrow et al., 2017b). Whole exome sequencing from over 500
trios identified a clear excess of likely gene-disrupting de novo
mutations, and 4 risk genes that were altered by different
mutations in multiple probands (Willsey et al., 2017). Another
report described whole exome sequencing in a 3-generation
family with TS, using induced pluripotent stem cells converted
into neuronal cell types and assessing protein expression levels
(Sun et al., 2018). The PNKD gene product was expressed
at a lower rate in family members with TS or OCD.

New insights from computational modelling. Using the neurophysiological data obtained from a TS animal model of
pharmacological striatal disinhibition, Caligiore et al. (2017)
proposed a computational model of the basal ganglia-cerebellarthalamo-cortical system to address the mechanisms of motor
tic generation in TS. Overall, the model suggested that interplay between dopaminergic signal and cortical activity triggered
the occurrence of a tic and was able to predict the number of
tics generated when striatal dopamine increases and when the
cortex is externally stimulated. Maia & Conceição (2017) further
discussed the role of tonic and phasic dopamine in tics learning
and expression. Based on the existing literature of habit formation and reinforcement learning in TS, the authors proposed a
model of tics as exaggerated and persistent motor habits reinforced by aberrant, increased phasic dopamine responses.
According to this model, tonic dopamine release would serve to
amplify the tendency to execute learned tics. The authors also proposed the mechanism of antipsychotics’ action on tics: increased
activity of indirect pathway due to antipsychotic administration
could result in tic reduction, but at the same time potentially
also could increase the propensity for reinforcing tics due to
plasticity in the indirect pathway. In contrast, the authors also
suggested that low-dose dopamine agonists could decrease both
phasic and tonic dopamine and thus reduce both tic learning and
tic expression. Both of these reports assume increasing tics with
increasing dopamine concentrations, an assumption that seems to
contradict observations that tics do not worsen with exogenous
levodopa (Black & Mink, 2000; Gordon et al., 2013) nor improve
with development of Parkinson disease (Kumar & Lang, 1997;
Martinez-Torres et al., 2009; Shale et al., 1986). Furthermore,
low-dose pergolide in children and adolescents with TS that
reduced tic severity suppressed prolactin rather than increasing it, consistent with overall enhancement of dopamine transmission, at least in the hypothalamic-pituitary dopaminergic
pathway (Gilbert et al., 2000a; Gilbert et al., 2000b).

Pathophysiology
Roger Albin wrote a very thoughtful review of TS as “a
disorder of the social decision-making network” (Albin, 2018).
Beste & Münchau (2018) describe tics in the context of the
Theory of Event Coding, which describes the brain’s bidirectional pairing of stimulus and movement. They note the salience
of urges to most tic patients, and the fact that most tics are
individually relatively normal movements, but occur repeatedly and out of context. Similarly, Shafer et al. (2017) focus on
the strong connections between movement and sensory function
to propose a theory that encompasses both the development
of stereotypies as part of typical development and their persistence
in maladaptive forms.
Animal models. A special issue on animal models of TS
appeared in the Journal of Neuroscience Methods (Bortolato & di
Giovanni, 2017). Articles reviewed gait and sensorimotor function in the D1CT-7 mouse model of TS (Fowler et al., 2017),
stress mediating the timing of abnormal movements in animal
models (Godar & Bortolato, 2017), and chemogenetic and
optogenetic models (Burton, 2017). Deer mice have behavior
that has been discussed as a natural model of OCD (Wolmarans
et al., 2018).
Recently postnatal ablation of the TrkB receptor in cells
expressing parvalbumin was shown to produce dramatic changes
in cortex and cerebellum and “profound hyperactivity, stereotypies, motor deficits and learning/memory defects” (Xenos
et al., 2017). This result may help explain why autopsies in
TS show a lower number of parvalbumin-containing interneurons in the striatum, but this model also produces much more
substantial neuroanatomical changes than are seen in TS.

Based largely on available functional anatomical studies,
Conceição et al. (2017) also proposed a computational model
of premonitory urges in TS. According to this model, premonitory urges and in particular their termination, like termination
of other aversive stimuli, might elicit positive prediction errors,
supported by phasic dopamine release that would then reinforce tics. The insula may play a central role in aversive feeling
associated with premonitory urges and their learned negative
value. The insula might send this information via direct or
indirect projections to dopamine neurons, which might use it
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for calculation of the positive prediction errors that occur with
termination of the premonitory urge. In short, the authors
provide a more detailed neurobiological explanation for the
classic model that premonitory urges may strengthen tics
through negative reinforcement.
Cognitive function and decision-making in TS. Morand-Beaulieu et al. (2017a) provide an updated and exhaustive review of
neuropsychological aspects of TS (compare Eddy et al. (2009)).
The review highlighted the slight alteration of social cognition
as well as more frequent learning difficulties and disabilities in children with TS. Recent data also seem to confirm the
deficit in executive function in TS as indexed by poor performance in continuous performance test and Stroop tests.
Interestingly, using longitudinal evaluation of executive function
in children with TS, Yaniv et al. (2018) showed that adults with
TS showed response inhibition deficits, that tic reduction over
time was significantly associated with development of response
inhibition, and that former TS patients whose tics had remitted
performed as well as, or on some tests better than, healthy
control subjects. In contrast, the attentional and memory capacity
seems to be impacted by comorbid symptoms more than TS per
se. Sample size (n=122) or the healthy control group may explain
different results obtained by Abramovitch et al. (2017), who
studied treatment response in TS. They concluded that “the finding that significant change in symptom severity of TS/CTD
patients is not associated with impairment or change in inhibitory
control regardless of treatment type suggests that inhibitory
control [as measured by the tests selected] may not be a
clinically relevant facet of these disorders in adults.” Given
these contradictory results, Morand-Beaulieu et al. (2017b)
review the puzzling question of inhibitory control in TS in a
recent meta-analysis, and find larger inhibitory deficits in TS +
ADHD patients, but this deficit was also present in “pure” TS.
This deficit in TS was most prominent in verbal responses, was
associated with tics severity as assessed with Yale Global Tic
Severity Scale-Total Tics Score (YGTSS-TTS) and was larger in
studies that included medicated TS patients.
Salvador et al. (2017) study decisional capacities in TS and
specifically the ability to learn from the outcomes of alternative
courses of action (known as counterfactual learning). Unmedicated patients with TS showed normal performance on this task,
whereas alteration was found in TS patients treated with the
dopamine D2-like receptor (D2R) partial agonist aripiprazole,
suggesting that modulating D2Rs may impair certain aspects
of human reinforcement learning.
The Committee on Research of the American Neuropsychiatric
Association published a systematic review on the neurobiology of
the premonitory urge in TS (Cavanna et al., 2017).
Electrophysiology. Brandt et al. (2017) reported on enhanced
multi-component behavior in TS, which was also reflected in
a smaller P3 event-related potential measured by EEG and
potentially related to chronic tic control in these patients. An
EEG study during simulated driving found that “mind wandering” may be quantifiable using EEG measures of alpha power
and the P3a component of an auditory event-related potential

(Baldwin et al., 2017). Since mind wandering is a defining
feature of ADD, in addition to being ubiquitous during repetitive tasks, these measures may prove useful in studying ADHD
phenomenology in TDs.
Neuroimaging studies. Polyanska & colleagues (2017) provide a
meta-analysis of task-based neuroimaging reports in TS. Adults
with TS show some impairment in lateralized sequential finger
tapping movements, and this impairment was compared to fractional anisotropy of white matter tracts connecting primary
motor cortex (M1) to M1 and supplementary motor area
(SMA) to SMA (Martino et al., 2017a).
Previous in vivo MRI studies of basal ganglia volume and shape
in TS have produced differing results (reviewed in Greene
et al. (2017)). A study of 47 children age 8-12 with TS, and
controls with or without ADHD, found no significant group
differences (Forde et al., 2017).
A PET study of the microglial activating marker TSPO in OCD
found elevated TSPO concentrations in dorsal caudate, orbitofrontal cortex, thalamus, ventral striatum, dorsal putamen,
and anterior cingulate cortex (Attwells et al., 2017). Concentrations in patients were about 1/3 higher than in controls.
This report implicates low-level brain inflammation in the
pathophysiology of OCD.
Clinical and neuropsychological studies. A study using the
alternating serial reaction time task found no impairment of procedural learning in TS or ADHD (Takács et al., 2017). This result
is surprising, given that habit learning on a “weather prediction”
task is slower in TS (Kéri et al., 2002; Marsh et al., 2004),
but may indicate that the two tasks engage different learning
systems, a conclusion supported by the generally normal
cognitive function in TS.
Münchau and colleagues extended their previous work on echopraxia (imitation) to children with TS (Brandt et al., 2017).
Participants were asked to lift either their index or pinky
finger when prompted by an auditory tone; simultaneously
they were shown a compatible or incompatible visual stimulus.
Children with TS were slower overall but thereby gained less
interference from the incompatible stimulus. The authors
conclude that these results suggest that children with TS may
employ “different or additional inhibition strategies” than
children without tics. Again, on this task children with TS show
superior, not deficient, action inhibition.

Treatment
Ganos et al. (2017) review treatments for TDs in children.
Psychological interventions. Houghton et al. (2017) analyzed
their existing data to test the longstanding theory that habituation to premonitory urges during adequate periods of tic
suppression is the mechanism by which behavior therapies for
tic disorders exerted their beneficial effects. In two previous
randomized trials, 126 children and adolescents and 122 adults
with TS or a persistent TD had been assigned to Comprehensive Behavioral Intervention for Tics (CBIT) or to education
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and supportive therapy. The prediction was that urge severity would decrease in CBIT responders. Surprisingly, however,
children showed no significant reduction in premonitory urges
with treatment, even though CBIT was quite effective in the child
study, and declines in urges in adults had no association
with clinical improvement or group assignment. The authors
conclude that habituation cannot be the underlying process
by which CBIT exerts its beneficial effects. This important result
warrants further study.
Another report from the same data set examined what clinical
features at baseline predicted improvement in tics during
treatment (Sukhodolsky et al., 2017). Importantly, those treated
with CBIT improved regardless of medication status, while in
the control (supportive therapy) group, tics improved only in
those taking medication for tics. Also importantly for the understanding of behavior therapy in TS and patient selection, other
psychiatric symptoms, age, sex, family functioning, and expectation of improvement had no significant effects on benefit from
therapy. And contrary to some opinions, patients with worse tic
severity had significantly better improvement in tics with CBIT.
Anxiety disorders and, surprisingly, more severe premonitory
urges predicted less improvement.
O’Connor and colleagues published a book describing their combined psychotherapeutic approach to tics (O’Connor et al., 2017).
Several groups reported efforts to increase dissemination and
use of behavior therapy for tics. An internet-based, therapist-guided behavior therapy for tics is being studied in the
BiP-TIC project (Karlsson, 2016). The TicHelper.com internet-based CBIT program went live in late 2017 and received a
positive review (Conelea & Wellen, 2017).
Medication. A group of international experts provided a status
report and recommendations for using brain imaging for the
rational development of novel psychopharmacological interventions (Suhara et al., 2017). As an example, a fascinating study in
pediatric ADHD showed that fMRI response to a cognitive task
(Go/No-Go) strongly predicted better clinical response to methylphenidate than to atomoxetine (Schulz et al., 2017). As the authors
conclude, “These data do not yet translate directly to the clinical setting, but the approach is potentially important for informing future research and illustrates that it may be possible to
predict differential treatment response using a biomarker-driven
approach.”
Initial results from the first randomized, controlled trial (RCT)
with a dopamine D1 receptor antagonist in pediatric TS were
released by the sponsor in January, 2017 (Chipkin, 2017).
These new results supported the positive results from a pilot
study in adults with TS (Gilbert et al., 2014), and suggest
a novel treatment mechanism for tics.
In April, the US FDA approved the presynaptic dopamine depleting agent valbenazine (Ingrezza®) for treatment of tardive
dyskinesia (Neurocrine Biosciences, Inc. 2017b). TS is a likely
off-label use for the drug, as the company has been conducting studies in children and adults with TS (ClinicalTrials.gov).

The FDA designated valbenazine an orphan drug for pediatric
patients with TS (Neurocrine Biosciences, Inc. 2017a). Another
VMAT2 inhibitor, tetrabenazine, has been used for some time
in the treatment of TS (Marsden, 1973; Sweet et al., 1974;
Jankovic, 2016). A related compound, deutetrabenazine (Paton,
2017), showed initial positive results in TS (Jankovic et al., 2016),
and the FDA approved it for treatment of tardive dyskinesia in
August (Business Wire, 2017).
Aripiprazole has become a drug of choice in treating tics and
comorbidities in TS over the past decade. However, large
scale trials have been missing. Moreover, aripiprazole is not
marketed for children and adolescents in many countries,
regardless of the indication. Sallee et al. (2017) report on a
phase 3, randomized, double-blind, placebo-controlled trial in
133 pediatric patients randomized in a 1:1:1 ratio to low-dose
aripiprazole (5 mg/day if <50 kg; 10 mg/day if ≥50 kg), highdose aripiprazole (10 mg/day if <50 kg; 20 mg/day if ≥50 kg),
or placebo for 8 weeks. The primary efficacy endpoint was
mean change from baseline to week 8 in the YGTSS-TTS. The
Clinical Global Impression-Tourette’s Syndrome improvement
score was also evaluated. High-dose aripiprazole was more
effective than low-dose aripiprazole, and both were superior
to placebo. Importantly, tolerance was overall good and no
serious adverse events or deaths occurred, indicating that oral
aripiprazole is a safe and effective treatment for tics in children
and adolescents. These results provide important reassurance to
clinicians who have been using aripiprazole for TS for years now.
The placebo response rate (for the Clinical Global Impression
scale), though half the response rate in the active treatment
groups, was nevertheless surprisingly high (38%).
A small (N=34) RCT of guanfacine showed no meaningful
difference in effects on tic ratings or clinical impressions of
improvement between the drug and placebo groups (Murphy
et al., 2017). This result is important and surprising, given that
adrenergic α2 agonists have been seen as first-line treatment for
TS, especially in TS patients with ADHD (Hollis et al., 2016).
Both these studies show how important RCTs are to clinical
care in TS. Speaking of RCTs and guanfacine, a press release
reported that extended-release guanfacine showed superiority
to placebo in adults with ADHD (discussed here). The importance of this report comes primarily from the fact that data on
ADHD treatments are scarcer in adults than in children.
Cannabinoids for TS are increasingly being studied; a brief
summary of some of this work appears in Black (2017).
Neurosurgery. A fascinating study demonstrated in mice that
interfering electrical “beats” (similar to the beats one hears when
tuning one instrument to another) can be used to steer neuron
activation to focal sites in the brain without surgical electrode
implantation (Grossman et al., 2017). Much work remains to be
done to demonstrate feasibility, safety and efficacy in humans,
but this approach potentially could lead to noninvasive, focal brain
stimulation.
Welter et al. (2017) performed a randomized, double-blind,
controlled trial of deep brain stimulation (DBS) of the posterior
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and anterior internal globus pallidus for severe TS. The design
was very similar to that reported previously by Kefalopoulou
et al. (2015), and so were the results. The primary endpoint was
the difference in YGTSS score between the beginning and end
of the 3 month double-blind period. No significant differences
between groups were noted in YGTSS score change between
the beginning and the end of the 3 month double-blind period,
despite a slight improvement in the stimulated condition. However, after the end of the open stimulation period and further
parameter adjustment, results become significant compared to
baseline. Also, when turning the stimulators off in a blinded
fashion, YGTSS scores increased again to reach near baseline
levels. Overall, this study is most important in terms of optimal
study design. The stimulator programming period preceding the
blinded phases was likely too short and the parameters suboptimal (a choice intended to reduce unblinding). Future studies
will need to consider these results carefully.
A London center reported an analysis of GPi DBS data,
looking for the “sweet spot” for DBS for tic improvement
(Akbarian-Tefaghi et al., 2017). They report that “a region within
the ventral limbic GPi, specifically on the medial medullary lamina in the pallidum at the level of the AC-PC, was significantly
associated with improved tics but not mood or OCB outcome.”
Two patients with DBS to the fields of Forel experienced a good
outcome (Neudorfer et al., 2017).
TS patients undergoing DBS, independent of the surgical
target, usually require high stimulation parameters, leading
to short (2–3 years) battery life, meaning frequent and costly
battery replacements. Michael Okun and colleagues showed proof
of the principle that triggered rather than continuous DBS may
be helpful (Molina et al., 2017). In a single patient with medically refractory TS, a spectral feature in the 5- to 15-Hz band
was used as the control signal from bilateral leads in the
centromedian-parafascicular (Cm-Pf) region of the thalamus.
Significant tic improvement compared to baseline was observed
12 months after the procedure, similar to that obtained with
continuous DBS, and resulted in a 63% improvement in the
neurostimulator’s projected mean battery life. These so called
closed-loop systems are gaining traction in various CNS
diseases where DBS is applied, and this case report paves
the way in TS.
A report from the DBS group in the Netherlands called
attention to side effects over the course of treatment in TS
patients with thalamic DBS (Smeets et al., 2018). A subthalamic
nucleus (STN) DBS study in OCD reminds us that DBS can
cause side effects; STN stimulation at higher voltages caused
chorea-ballismus (Mulders et al., 2017).

Tics, family and society
Quality of life is lower in parents of children with TS and
is more related to factors other than tic severity (Jalenques
et al., 2017). Stewart et al. (2015) previously reported similar

results. These studies emphasize the need to assess and treat
symptoms other than tics in TS patients, and to care for the whole
patient.

Conclusions
2017 has again seen a rise in publications on TS, reflecting the
increased interest this field receives, both from clinicians and
researchers devoted to this disorder but also from adjoining fields,
given the substantial psychopathology associated with TDs.
One important question raised is the natural course of TS
and the rate of (non-)remission. Recent data suggest that the
optimistic outlook prevalent with regard to tic severity when
gliding from adolescence into adulthood might not be completely justified. Here, large longitudinal studies are warranted,
and also to better understand the prognostic factors associated
with tic remission or persistence. The fate of comorbidities also
needs to be better understood, even though data have begun to
emerge. We also still face important delays in the diagnosis of
TS, and we need to deal with the recently demonstrated increased
suicide risk in this condition, which underlines that TDs are far
from benign.
Of note, there is a rise in computational models of TS, which
provide important leads to understanding its pathophysiology
and will likely fuel more targeted treatment approaches for tics.
In the therapy field, 2017 has mainly seen studies centered on
well-known pharmacological targets such as the dopaminergic
system; however, new antidopaminergic medications were
studied or came to the market in 2017, and increasing data
supports existing off-label prescription practices. Behavioral
therapy continues to emerge as a main pillar of tic treatment,
with an improved understanding of its mechanisms and response
factors. In the surgical field, deep brain stimulation for severe
TS cases continues to draw interest; in particular, target choice,
length of stimulator programming for optimal outcome, and
closed-loop systems are under active investigation.
Overall, the field is active and burgeoning. Breakthroughs are
to be expected in the upcoming years, especially with regard
to large-scale efforts in the field.
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